Advances on the novel drug deliver system: Bacterial ghost

Progress in Biochemistry and Biophysics

Volumn 33, Issue 7, 2006, Pages 622-626

  Zhang, Rui Ping ^a   Zhang, Zhao Shan ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Bacterial; Bacterial ghost; Delivery system; Vaccine

Indexed keywords

BACTERIA (MICROORGANISMS);

EID: 33750306158     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Witte A, Lubitz W. Biochemical characterizationof PhiX174 protein E-mediated lysis of Escherichia coli. Eur J Biochem, 1989, 180 (2): 393-398
2. Witte A, Blaësi U, Halfmann G, et al. PhiX174 protein E-mediated lysis of Escherichia coli. Biochimie, 1990, 72(2-3): 191-200
3. Marchart J, Dropmann G, Lechleitner S, et al. Pasteurella multocida and Pasteurella haemolytica-ghosts: new vaccine candidates. Vaccine, 2003, 21 (25-26): 3988-3997
4. Jechlinger W, Szostak M, Witte A, et al. Altered temperature induction sensitivity of the lambda PR/cI857 system for controlled gene E-expression in Escherichia coli. FEMS Microbiol Lett, 1999, 173 (2): 347-352
5. Riedmann E, Kyd J, Smith A, et al. Construction of recombinant S-layer proteins (rSbsA) and their expression in bacterial ghosts - a delivery system for the nontypeable Haemophilus influenzae antigen Omp26. FEMS Immunol Med Microbiol, 2003, 37 (2-3): 185-192
6. Szostak M P, Hensel A, Eko F O, et al. Bacterial ghosts: non-living candidate vaccines. J Biotechnol,1996, 44 (1-3): 161-170
7. Eko F O, Witte A, Huter V, et al. New strategies for combination vaccines based on the extended recombinant bacterial ghost system. Vaccine,1999, 17 (13-14): 1643-1649
8. Halfmann G, Gotz F, Lubitz W. Expression of bacteriophage PhiX174 lysis gene E in Staphylococcus carnosus TM3000. FEMS Microbiol Lett, 1993, 108 (2): 139-143
9. Panthel K, Jechlinger W, Matis A, et al. Generation of Helicobacter pylori ghosts by PhiX protein E-mediated inactivation and their evaluation as vaccine candidates. Infect Immun, 2003, 71 (1): 109-116
10. Haidinger W, Mayr U B, Szostak M P, et al. Escherichia coli ghost production by expression lysis gene E and staphylococcal nuclease. Appl Environ Microbiol, 2003, 69 (10): 6106-6113
11. Haidinger W, Szostak M P, Jechlinger W, et al. Online monitoring of the Escherichia coli ghost production. Appl Environ Microbiol, 2003, 69 (1): 468-474
12. Katinger A, Lubitz W, Szostak M P, et al. Pigs aerogenously immunized with genetically inactivated (ghosts) or irradiated Actinobacillus pleuropneumoniae are protected against a homologous aerosol challenge despite differing in pulmonary recombicellular and antibody responses. J Biotech, 1999, 73 (2-3): 251-260
13. Hensel A, Huter V, Katinger A, et al. Intramuscular immunization with genetically inactivated (ghosts) Actinobacillus pleuropneumoniae serotype 9 protects pigs against homologous aerosol challenge and prevents carrier state. Vaccine, 2000, 18 (26): 2945-2955
14. Huter V, Hensel A, Brand E, et al. Improved protection against lung colonization by Actinobacillus pleuropneumoniae ghosts: characterization of a genetically inactivated vaccine. J Biotechnol, 2000, 83 (1-2): 161-172
15. Eko F O, Hensel A, Bunka S, et al. Immunogenicity of Vibrio cholerae ghosts following intra-peritoneal immunization of mice. Vaccine, 1994, 12 (14): 1330-1334
16. Eko F O, Schukovskaya T, Lotzmanova E Y, et al. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. Vaccine, 2003, 21 (25-26): 3663-3674
17. Mayr U B, Walcher P, Azimpour C, et al. Bacterial ghosts as antigen delivery vehicles. Advanced Drug Delivery Reviews, 2005, 57 (9): 1381-1391
18. Jechlinger W, Haller C, Resch S, et al. Comparative immunogenicity of the hepatitis B virus core 149 antigen displayed on the inner and outer membrane of bacterial ghosts. Vaccine, 2005, 23 (27): 3609-3617
19. Truppe M, Howorka S, Schroll G, et al. Biotechnological applications of recombinant Slayer proteins rSbsA and rSbsB from Bacillus stearothermophilus PV72. FEMS Microbiol Rev, 1997, 20: 47-98
20. Riedmann E, Kyd J, Smith A, et al. Construction of recombinant S-layer proteins (rSbsA) and their expression in bacterial ghosts-a delivery system for the nontypeable Haemophilus influenzae antigen Omp26. FEMS Immunol Med Microbiol, 2003, 37 (2-3): 185-192
21. Szostak M P, Auer T, Lubitz W. Modern Approaches to New Vaccines Including Prevention of AIDS. New York: Cold Spring Harbor Laboratory Press, 1993. 419-425
22. Eko F O, Lubitz W, Mcmillan L, et al. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis. Vaccine, 2003, 21 (15): 1694-1703
23. Paukner S, Kudela P, Kohl G. DNA-loaded bacterial ghosts efficiently mediate reporter gene transfer and expression in macrophages. Molecular therapy, 2005, 11 (2): 215-223
24. Mayrhofe P, Azimpour-Tabrizi C, Walcher P, et al. Immobilization of plasmid DNA in bacterial ghosts. J Control Release, 2005, 102 (3): 725-735
25. Paukner S, Kohl G, Lubitz W. Bacterial ghosts as novel advanced drug delivery systems: antiproliferative activity of loaded doxorubicin in human Caco-2 cells. J Control Release, 2004, 94 (1): 63-74
26. Paukner S, Kohl G, Jalava K, et al. Sealed bacterial ghosts-novel targeting vehicles for advanced drug delivery of water-soluble substances. J Drug Target, 2003, 11 (3): 151-161